Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06323928 · ClinicalTrials.gov registry record · Phase 2

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

A Phase 2 study of Migraine, sponsored by H. Lundbeck A/S.

Active
Registry status
Phase 2
Development phase
874
Enrollment target
20
Study locations

NCT06323928 is a Phase 2 study of Migraine that is active but no longer recruiting, run by H. Lundbeck A/S. The registered enrollment target is 874 participants, above the 350-participant average among 102 other Migraine trials with a reported enrollment target (150% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06323928, a Phase 2 study of Migraine, is active but no longer recruiting, sponsored by H. Lundbeck A/S.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
874 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.

Conditions Studied

Migraine

Interventions

  • DRUG Placebo
  • DRUG Lu AG09222

Study Locations (20)

Florida

  • K2 Medical Research - Winter Garden - Clermont
  • Clinical Neuroscience Solutions, Inc. - Jacksonville
  • K2 Medical Research, LLC - Maitland - Maitland
  • Aqualane Clinical Research - Naples
  • K2 Medical Research Tampa LLC - Tampa
  • Premiere Research Institute Palm Beach - West Palm Beach

California

  • Profound Research - Neurology Center of Southern California - Carlsbad
  • Neurology Center of North Orange County - Fullerton
  • CenExel CNS - Los Alamitos
  • ASCLEPES Research Centers - Sherman Oaks

North Carolina

  • Accellacare of Cary - Cary Medical Group - Cary
  • Headache Wellness Center - Greensboro
  • Raleigh Medical Group - Raleigh

Missouri

  • Clinical Research Professionals - Chesterfield
  • Healthcare Research Network - Hazelwood

New York

  • Dent Neurosciences Research Center, Inc. - Amherst
  • North Suffolk Neurology, PC. - Port Jefferson Station

Alabama

  • Accel Research Sites Network - Neurology and Neurodiagnostic of Alabama - Hoover

Connecticut

  • Ki Health Partners LLC DBA New England Institute for Clinical Research - Stamford

Iowa

  • Accellacare and McFarland Clinic - Ames

Trial Details

FieldValue
Enrollment Target 874 participants
Start Date 2024-04-01
Est. Completion 2026-04-30
Phase Phase 2

Sponsor

H. Lundbeck A/S

72 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06323928

The ClinicalTrials.gov registry entry for NCT06323928 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 874 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 350-participant average among 102 other Migraine trials with a reported enrollment target (150% higher). The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06323928 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06323928 about?

NCT06323928 is a clinical study titled "A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments". The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.

What is the current status of trial NCT06323928?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 874 participants. The study started on 2024-04-01. Estimated completion is 2026-04-30.

What conditions does trial NCT06323928 study?

This clinical trial studies the following conditions: Migraine.

What interventions are being tested in trial NCT06323928?

The interventions under investigation include: Placebo (DRUG), Lu AG09222 (DRUG).

Who is sponsoring clinical trial NCT06323928?

This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06323928 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Migraine

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.